Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Why blood sugar rises: beta cells and the long decline

Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Insulin resistance explains why the body needs more insulin. The pancreas explains why, eventually, it does not get it.

Understanding this side of the disease answers one of the most demoralising questions people ask: why am I doing everything right and still needing more treatment?

Related pages: Type 2 diabetes

The bottom line

What we know
  • Beta-cell function is already substantially reduced at the point of diagnosis.
  • The decline continues over years in most people regardless of which medicine is used.
  • The incretin effect, in which gut hormones amplify insulin release after eating, is blunted in type 2 diabetes.
  • Glucagon from alpha cells remains inappropriately high, adding to the problem.
  • Substantial weight loss can restore a meaningful amount of beta-cell function in some people, particularly early on.
What is still open
  • Whether beta-cell loss is mainly death or reversible dedifferentiation.
  • Whether any drug class truly alters the underlying trajectory.
  • Why the decline is much faster in some people than others.

The story, step by step

  1. 1. The cells ()
  2. 2. The decline ()
  3. 3. The gut ()
  4. 4. The other hormone ()
  5. 5. The reversal ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

What beta cells do

Review of many studies

What happens

A minority population with an outsized job.

What the research shows

  • Beta cells sit in clusters called islets of Langerhans, scattered through the pancreas. They make up a small fraction of the organ's mass.
  • They sense glucose directly and release insulin in two phases: a rapid burst within minutes, then a sustained second phase.
  • The first-phase burst is lost early in type 2 diabetes, which is a major reason blood sugar spikes after meals before fasting levels rise.
  • Insulin is also released in regular pulses, and this pulsatility is disturbed early.
  • Alpha cells in the same islets release glucagon, which raises blood sugar. The two are normally in balance.
  • Delta cells and others fine-tune the output, making the islet a small integrated organ rather than a simple gland.

Why it matters

Loss of the first-phase burst explains why post-meal spikes appear before fasting numbers do, and why A1C can be rising while fasting glucose still looks acceptable.

What's still uncertain

  • Why first-phase release is so vulnerable.
  • Whether restoring pulsatility would be clinically useful.

Read more

Next: The decline

Part 2 of 5

What the long-term studies showed

Review of many studies

What happens

Function falls steadily after diagnosis.

What the research shows

  • Long-term follow-up in large trials showed beta-cell function declining progressively over years in most participants, whatever treatment they received.
  • A1C tends to drift upward over time on a fixed regimen, which is the clinical face of that decline.
  • This is why most people eventually need combination therapy, and why some need insulin after a decade or more.
  • The rate varies widely. Some people remain controlled on one medicine for twenty years; others progress in three.
  • Younger age at diagnosis is associated with faster decline and a higher lifetime complication burden, which is why diabetes in young adults is treated as the more aggressive form.
  • Earlier good control appears to carry benefit that persists for years afterwards, an effect described as metabolic memory or legacy.

Why it matters

Needing a second or third medicine usually means the disease has progressed as expected, not that the person has done something wrong. The framing matters, because self-blame drives people away from care.

What's still uncertain

  • How much of the decline is modifiable.
  • Which early treatment strategy best preserves function.

Read more

Next: The gut

Part 3 of 5

Incretins and why they matter

Review of many studies

What happens

Hormones that amplify insulin after food.

What the research shows

  • Glucose taken by mouth triggers far more insulin release than the same amount given intravenously. The difference is the incretin effect, caused by gut hormones released during digestion.
  • The two main incretins are GLP-1 and GIP. Both amplify insulin release, but only when glucose is high, which is why they do not cause low blood sugar by themselves.
  • GLP-1 also suppresses glucagon, slows stomach emptying and reduces appetite through the brain.
  • The incretin effect is markedly reduced in type 2 diabetes, with the response to GIP particularly impaired.
  • This biology is the basis of two modern drug classes: GLP-1 receptor agonists, which supply a long-acting version of the hormone, and DPP-4 inhibitors, which slow its breakdown.
  • Dual agonists acting on both GLP-1 and GIP receptors produce larger effects on both blood sugar and weight.

Why it matters

The incretin story is the clearest case where understanding the mechanism produced genuinely better drugs rather than incremental ones.

What's still uncertain

  • Why GIP responsiveness is lost and whether it can be restored.
  • The long-term durability of incretin-based treatment.

Read more

Next: The other hormone

Part 4 of 5

Glucagon's role

Review of many studies

What happens

The liver gets the wrong instruction.

What the research shows

  • Glucagon tells the liver to release stored glucose and to make new glucose. It is the counterweight to insulin.
  • In type 2 diabetes, glucagon levels fail to fall normally after a meal and are often inappropriately high.
  • The result is that the liver continues releasing glucose while the person is eating, adding to the post-meal rise.
  • Fasting glucose, the number people see first thing in the morning, is driven largely by overnight liver glucose production rather than by anything eaten.
  • This is why metformin, which reduces liver glucose production, lowers fasting glucose effectively.
  • It also explains the dawn phenomenon, a rise in blood sugar in the early morning hours driven by normal hormone cycles.

Why it matters

A high morning reading is usually the liver, not last night's dinner. Knowing that prevents a lot of misdirected effort.

What's still uncertain

  • Whether suppressing glucagon directly is a safe therapeutic route.
  • How much of the dawn phenomenon can be managed with timing of medication.

Read more

Next: The reversal

Part 5 of 5

What remission shows

Review of many studies

What happens

Some of the loss is recoverable.

What the research shows

  • Studies of substantial weight loss, through very low calorie diets or bariatric surgery, found blood sugar returning to the non-diabetic range in a sizeable share of participants.
  • Liver fat falls within days to weeks, and fasting glucose improves quickly alongside it.
  • Pancreatic fat falls more slowly, and the recovery of first-phase insulin release follows that slower course.
  • Remission is most likely in those diagnosed within the last few years and who lose the most weight.
  • Remission is defined as an A1C below the diabetic range for at least three months without glucose-lowering medicine. It is not a cure, and monitoring continues.
  • Weight regain is usually followed by a return of high blood sugar, which points to the mechanism rather than to a failure of the person.

Why it matters

Beta-cell failure is not uniformly permanent. That changes the ambition of early treatment from control to possible reversal.

What's still uncertain

  • How long remission lasts and in whom.
  • Whether newer weight-loss medicines produce equivalent beta-cell recovery.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.